Thrombophilia and Adverse Maternal-Perinatal Outcome: Controversies in Screening and Management

ABSTRACT

A recent review of the literature on thrombophilia and adverse pregnancy outcome reveals contradictory findings. There are retrospective and prospective studies that recommend testing for genetic and acquired markers of thrombophilia for those with the enumerated adverse pregnancy outcome. Based on our review, routine screening for thrombophilias in women with a history of adverse pregnancy outcome (preeclampsia, abruptio placenta, intrauterine growth restriction, and fetal loss) is not justified. Based on data from observational studies and few randomized trials with inadequate number of subjects, there is consensus that women with true antiphospholipid antibody syndrome should receive low-dose aspirin plus adjusted-dose heparin in subsequent pregnancies. Some authors also recommend heparin prophylaxis in subsequent pregnancies in women with genetic thrombophilia with previous adverse pregnancy outcome. However, this recommendation is not based on randomized trials. Hence, a randomized double-blind, controlled trial is urgently needed to evaluate the benefit of heparin during pregnancy in women with a history of adverse pregnancy outcome in association with genetic thrombophilia.

KEYWORDS

Thrombophilia - adverse pregnancy outcome

REFERENCES

• 1 Paidas M J, De-Hui W K, Arkel Y S. Screening and management of inherited thrombophilias in the setting of adverse pregnancy outcome.  Clin Perinatol. 2004;  31 783-805
• 2 Barbour L A. Thromboembolism in pregnancy. ACOG Committee in Obstetric Practice Bulletin. Number 19. Washington, DC; The College 2000
• 3 Rey E, Kahn S R, David M, Shrier I. Thrombophilic disorders and fetal loss: a metaanalysis.  Lancet. 2003;  361 901-908
• 4 Ridker P M, Miletich J P, Hennekens C H, Burring J E. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening.  JAMA. 1997;  277 1305-1307
• 5 Dizon-Townson D, Miller C, Sibai B et al.. The relationship of factor V Leiden mutation and pregnancy outcomes for mother and fetus.  Obstet Gynecol. 2005;  106 517-524
• 6 Lockwood C J. Inherited thrombophilias in pregnant patients.  Prenat Neonat Med. 2001;  6 3-14
• 7 Greer I A. Thrombophilia: implications for pregnancy outcome.  Thromb Res. 2003;  109 73-81
• 8 Rosendaal F R. Venous thrombosis: a multicausal disease.  Lancet. 1999;  353 1167-1173
• 9 Lee R M, Brown M A, Branch D W, Ward K, Silver R M. Anticardiolipin and anti- B2 glycoprotein-I antibodies in preeclampsia.  Obstet Gynecol. 2003;  102 294-300
• 10 Kujovich J L. Thrombophilia and pregnancy complications.  Am J Obstet Gynecol. 2004;  191 412-424
• 11 Lin L, August P. Genetic thrombophilias and preeclampsia: a meta-analysis.  Obstet Gynecol. 2005;  105 182-192
• 12 Mignini L E, Latthe P M, Villar J, Killy M D, Carroli G, Khan K S. Mapping the theories of preeclampsia: the role of homocysteine.  Obstet Gynecol. 2005;  105 411-425
• 13 Ananth C V. Placental abruption and perinatal mortality in the United States.  Am J Epidemiol. 2001;  153 332-337
• 14 Branch D W, Porter T F, Rittenhouse L et al.. Antiphospholipid antibodies in women at risk for preeclampsia.  Am J Obstet Gynecol. 2001;  184 825-834
• 15 Dreyfus M, Hedelin G, Kutnahorsky R et al.. Antiphospholipid antibodies and preeclampsia: a case-control study.  Obstet Gynecol. 2001;  97 29-34
• 16 Lee R M, Brown M A, Branch D W, Ward K, Silver R M. Anticardiolipin and anti-β₂-glycoprotein-1 antibodies in preeclampsia.  Obstet Gynecol. 2003;  102 294-300
• 17 Esplin M S. Antiphospholipid syndrome. ACOG Practice Bulletin No. 68.  Obstet Gynecol. 2005;  106 1113-1121
• 18 Dekker G A, de Vries J I, Doelitzsch P M et al.. Underlying disorders associated with severe early-onset preeclampsia.  Am J Obstet Gynecol. 1995;  173 1042-1048
• 19 Dizon-Townson D S, Nelson L M, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia.  Am J Obstet Gynecol. 1996;  175 902-905
• 20 Riyazi N, Leeda M, de Vries J IP, Huijgens P C, van Geijn H P, Dekker G A. Low molecular weight heparin combines with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study.  Eur J Obstet Gynecol Reprod Biol. 1998;  80 49-54
• 21 Nagy B, Toth T, Rigo Jr J, Karadi I, Romics L, Papp Z. Detection of factor V Leiden mutation in severe preeclamptic Hungarian women.  Clin Genet. 1998;  53 478-481
• 22 Krauss T, Augustin H G, Osmers R, Meden H, Unterhalt M, Kuhn W. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome.  Obstet Gynecol. 1998;  92 457-460
• 23 Kupferminc M J, Eldor A, Steinman N et al.. Increased frequency of genetic thrombophilia in women with complications of pregnancy.  N Engl J Med. 1999;  340 9-13
• 24 van Pampus E C, Dekker G A, Wolf H et al.. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia.  Am J Obstet Gynecol. 1999;  180 1146-1150
• 25 DeGroot C J, Bloemankamp K W, Duvekot E J et al.. Preeclampsia and genetic factors for thrombosis: a case control study.  Am J Obstet Gynecol. 1999;  181 975-980
• 26 Kupferminc M J, Fait G, Many A, Girdon D, Eldor A, Lessing J B. Severe preeclampsia: high frequency of genetic thrombophilic mutations.  Obstet Gynecol. 2000;  96 45-49
• 27 Rigo J, Nagy B, Fintor L, Tanyi J, Beke A, Karadi I, Papp Z. Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutations and 5,10 methylenetetrahydrofolate reductase.  Hypertens Pregnancy. 2000;  19 163-172
• 28 von Tempelhoff G F. Incidence of factor V Leiden mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP syndrome (hemolysis, elevated liver enzymes, low platelets).  Thromb Res. 2000;  100 363-365
• 29 Kupferminc M J, Peri H, Zwang E, Yaron Y, Wolman I, Eldor A. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss.  Acta Obstet Gynecol Scand. 2000;  79 963-967
• 30 Kim Y J, Williamson R A, Murray J C et al.. Genetic susceptibility to preeclampsia: roles of cytosine-to-thymine substitution at nucleotide 677 of the gene for methytetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathione [beta]-synthase, and factor V Leiden mutation.  Am J Obstet Gynecol. 2001;  184 1211-1217
• 31 Livingston J C, Barton J R, Park V, Haddad B, Phillips O, Sibai B M. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia.  Am J Obstet Gynecol. 2001;  185 153-157
• 32 Currie L, Peek M, McNiven M, Prosser I, Mansour J, Ridgway J. Is there an increased maternal-infant prevalence of factor V Leiden in association with severe pre-eclampsia?.  BJOG. 2002;  109 191-196
• 33 Benedetto C, Marozio L, Salton L, Maula V, Chieppa G, Massobrio M. Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome.  Acta Obstet Gynecol Scand. 2002;  81 1095-1100
• 34 Schlembach D, Beinder E, Zingsem J, Wunsiedler U, Beckmann M W, Fischer T. Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth restriction.  Clin Sci. 2003;  105 279-285
• 35 Mello G, Parretti E, Marozio L et al.. Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study.  Hypertension. 2005;  46 1270-1274
• 36 Stanley-Christian H, Ghidini A, Sacher R, Shemirani M. Fetal genotype for specific inherited thrombophilias is not associated with severe preeclampsia.  J Soc Gynecol Investig. 2005;  12 198-201
• 37 Prochaska M, Happach C, Marsal K, Dahlback B, Lindqvist P G. Factor V Leiden in pregnancies complicated by placental abruption.  Br J Obstet Gynaecol. 2003;  110 462-466
• 38 Hira B, Pegoraro R J, Rom L, Govender T, Moodley J. Polymorphisms in various coagulation genes in black South African women with placental abruption.  BJOG. 2002;  109 574-575
• 39 Kupferminc M J, Fait G, Many A et al.. Low molecular weight heparin for the prevention of obstetric complications in women with thrombophilias.  Hypertens Pregnancy. 2001;  20 35-44
• 40 Infante-Rivard C, Rivard G E, Yotov W V et al.. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction.  N Engl J Med. 2002;  347 19-25
• 41 Verspyck E, Borg J Y, Le Cam-Duchez V et al.. Thrombophilia and fetal growth restriction.  Eur J Obstet Gynecol Reprod Biol. 2004;  113 36-40
• 42 McCowan L ME, Craigie R M, Taylor R S, Ward C, McLintock C, North R A. Inherited thrombophilias are not increased in “idiopathic” small-for-gestational-age pregnancies.  Am J Obstet Gynecol. 2003;  188 981-992
• 43 Kupferminc M J, Many A, Bar-Am A, Lessing J B, Ascher-Landsberg J. Mid-trimester severe intrauterine growth restriction is associated with high prevalence of thrombophilia.  BJOG. 2002;  109 1373-1376
• 44 Howley H E, Walker M, Rodger M A. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction.  Am J Obstet Gynecol. 2005;  192 694-708
• 45 Martinelli I, Taioli E, Cetin I et al.. Mutations in coagulation factors in women with unexplained late fetal loss.  N Engl J Med. 2000;  343 1015-1018
• 46 Gonen R, Lavi N, Attias D et al.. Absence of association of inherited thrombophilia with unexplained third-trimester intrauterine fetal death.  Am J Obstet Gynecol. 2005;  192 742-746
• 47 Many A, Elad R, Yaron Y, Eldor A, Lessing J, Kupferminc M J. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia.  Obstet Gynecol. 2002;  99 684-687
• 48 Hefler L, Jirecek S, Heim K et al.. Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study.  J Soc Gynecol Investig. 2004;  11 42-44
• 49 Sibai B M, El-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primagravid women: subsequent pregnancy outcome and remote prognosis.  Am J Obstet Gynecol. 1986;  155 1011-1016
• 50 Sibai B M, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis.  Am J Obstet Gynecol. 1991;  165 1408-1412
• 51 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J S. Gestational outcome in thrombophilix women with recurrent pregnancy loss treated with enoxaparin.  Thromb Haemost. 2000;  83 693-697
• 52 Ogueh O, Chen M F, Spurll G, Benjamin A. Outcome of pregnancy in women with hereditary thrombophilia.  Int J Gynaecol Obstet. 2001;  74 247-253
• 53 Grandone E, Brancaccio V, Colaizzo D et al.. Preventing adverse obstetric outcomes in women with genetic thrombophilia.  Fertil Steril. 2002;  78 371-375
• 54 Kutteh W H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.  Am J Obstet Gynecol. 1996;  174 1584-1589
• 55 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipids antibodies (or antiphospholipid antibodies).  BMJ. 1997;  314 253-257
• 56 Silver R K, MacGregor S N, Sholl J S, Hobart J M, Neerhof M G, Ragin A. Comparative trial of prednisone versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients.  Am J Obstet Gynecol. 1993;  169 1411-1417
• 57 Pattison N S, Chamley L W, Birdsall M, Zanderigo A M, Liddell H S, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial.  Am J Obstet Gynecol. 2000;  183 1008-1012
• 58 Farquharson R G, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment.  Obstet Gynecol. 2002;  100 408-413
• 59 Gris J C, Mercier E, Quere I et al.. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder.  Blood. 2004;  103 3695-3699
• 60 Branch D W, Khamashta M A. Antiphospholipid syndrome: obstetric diagnosis, management and controversies.  Obstet Gynecol. 2003;  101 1333-1344
• 61 Rotmensch S, Liberati M, Mittleman M, Ben Rafael Z. Activated protein C resistance and adverse pregnancy outcome.  Am J Obstet Gynecol. 1997;  177 170-173
• 62 Leeda M, Riyazi N, de Vries J I, Jakobs C, van Geijn H P, Dekker G A. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia of fetal growth restriction.  Am J Obstet Gynecol. 1998;  179 135-139